Sep. 21 at 8:07 PM
$DYAI It is not accurate to say they are pre-revenue. They sold their industrial production rights to Dupont for
$70M in 2015, and prior to that, they were getting revenue from their protein production platform. They have refined the C1 platform since then, and they do not have a lot of R&D spend.